Amendment 001_Synthesis Services for Custom Biomolecules for Detection of Mutation-Reactive T cells in Patients With Metastatic Cancers
Closed Solicitation Posted
- Solicitation number
- 75N91024Q00094
- Agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 621511 Medical Laboratories
- PSC
- Q301 Reference Laboratory Testing
- Place of performance
- Bethesda, Maryland 20892, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Surgery Branch (SB) is seeking synthesis services for custom biomolecules to support the detection of Mutation-Reactive T cells in patients with Metastatic Cancers. This is a Request for Quote (RFQ) for commercial items, processed in accordance with FAR 13.5. One firm fixed price award is anticipated. Vendors must submit questions by 12:00PM EDT on 08/08/2024 and quotes by 6:00PM EDT on 08/12/2024 via email. Quotes will be evaluated based on price reasonableness and best value to the government.
This opportunity is not set-aside. The government anticipates making a single award, but has not identified any potential incumbents or current contractors. The award value and precise quantities of biomolecules required are not specified. The place of performance is Bethesda, MD 20892, USA.
Notice text
2 versions
Update #2 · Latest ·
The purpose of Amendment 001 is to attach PDF "52.212-3(MAY2024)_FullText." Response date remains unchanged.
***Please read the attached documents***
The Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR), Surgery Branch (SB) requires synthesis services for custom biomolecules for the detection of Mutation-Reactive T cells in patients with Metastatic Cancers.
This is a Combined Synopsis/Solicitation for commercial items, prepared in accordance with the format in Federal Acquisition Regulation (FAR) subpart 12.6, as supplemented with additional information included in this notice, and shall be processed in accordance with FAR 13.5 - Simplified Procedures for Certain Commercial Products and Commercial Services. This announcement constitutes the only solicitation that will be provided in relation to the stated need contained herein. This solicitation is issued as a Request for Quote (RFQ) and includes applicable provisions and clauses in effect through FAR Federal Acquisition Circular (FAC) 2024-05 (05/22/2024).
One firm fixed priced award is anticipated to be made as a result of this solicitation.
Please submit questions concerning this RFQ via email no later than 12:00PM EDT on Thursday, 08/08/2024.
Quotes in response to this RFQ must be submitted via email no later than 6:00PM EDT on Monday, 08/12/2024.
Update #1 ·
***Please read the attached documents***
The Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR), Surgery Branch (SB) requires synthesis services for custom biomolecules for the detection of Mutation-Reactive T cells in patients with Metastatic Cancers.
This is a Combined Synopsis/Solicitation for commercial items, prepared in accordance with the format in Federal Acquisition Regulation (FAR) subpart 12.6, as supplemented with additional information included in this notice, and shall be processed in accordance with FAR 13.5 - Simplified Procedures for Certain Commercial Products and Commercial Services. This announcement constitutes the only solicitation that will be provided in relation to the stated need contained herein. This solicitation is issued as a Request for Quote (RFQ) and includes applicable provisions and clauses in effect through FAR Federal Acquisition Circular (FAC) 2024-05 (05/22/2024).
One firm fixed priced award is anticipated to be made as a result of this solicitation.
Please submit questions concerning this RFQ via email no later than 12:00PM EDT on Thursday, 08/08/2024.
Quotes in response to this RFQ must be submitted via email no later than 6:00PM EDT on Monday, 08/12/2024.
Files
| File | Type | Posted |
|---|---|---|
| 52.212-3(MAY2024)_FullText.pdf | ||
| 75N91024Q00094_ComSynopSolicitation.pdf | ||
| RFQ 75N91024Q00094 - SOW.pdf |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Reagents and consumables for Roche immunostainers | Office of Logisitics and Acquisition Operations | No set-aside | |
| iPSC Culture and Differentiation | Office of Logisitics and Acquisition Operations | No set-aside | |
| Synthesis and Distribution of Drugs of Abuse and Related Compounds | National Institute on Drug Abuse | No set-aside | |
| 6550-- Roche Ventana Reagents IDIQ 5 Successive 1 Year Delivery Orders | Veterans Integrated Service Network 16 | No set-aside | |
| Clinical Research Support and Collaboration for NHGRI Protocols | Office of Logisitics and Acquisition Operations | Total Small Business |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity